Pediatric Obesity Management Market value of US$ 3.2 Billion in 2023 | FMI Study

The global paediatric obesity management market is anticipated to reach a market value of US$ 3.2 billion in 2023 and to reach US$ 4.74 billion by registering a CAGR of 4% from 2023 to 2033. From 2018 to 2022, the market for paediatric obesity management experienced a 3% CAGR.

The global prevalence of pediatric obesity has been increasing steadily over the past few decades, and it is now considered one of the most pressing public health challenges of our time. According to the World Health Organization, approximately 41 million children under the age of five were overweight or obese in 2016, and this number is expected to continue to rise in the coming years. Future Market Insights projects the global pediatric obesity management market to grow at a compound annual growth rate (CAGR) of 4% from 2023 to 2033.

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16761

New innovations in pediatric obesity management are providing children with effective tools to manage their weight and improve their overall health and well-being.

One of the most promising innovations in pediatric obesity management is the development of personalized nutrition and exercise plans. These plans take into account a child’s unique needs and preferences, as well as their medical history and any underlying conditions. By tailoring nutrition and exercise recommendations to each individual child, healthcare providers can help children achieve and maintain a healthy weight in a sustainable way.

Another promising innovation is the use of digital health tools, such as mobile apps and wearable devices, to monitor and manage pediatric obesity. These tools can help children and their families track their progress, set goals, and receive personalized feedback and support. By making it easier and more convenient to manage pediatric obesity, digital health tools are helping to improve patient compliance and outcomes.

Key Takeaways from the Market Study

• The market for paediatric obesity management expanded at a CAGR of 3% between 2018 and 2022.
• From 2023 to 2033, the global market for paediatric obesity management is anticipated to expand at a 4% CAGR.
• The Pediatric Obesity Management Market is anticipated to generate US$4.74 billion by 2033.
• According to the FMI analysis, hospital pharmacies account for the largest market share.
• In terms of market share for paediatric obesity management, North America is predicted to hold 40% of the market.
• With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Pediatric Obesity Management.” says an FMI analyst

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-16761

Market Competition

Key players in the market include companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AstraZeneca, Herbalife Ltd., Apollo Endosurgery, Ethicon, Inc., Takeda Pharmaceutical Company, VIVUS Inc., Currax Pharmaceuticals LLC, along with healthcare providers and technology companies among other global players.

• The U.S. Food and Drug Administration approved the use of Wegovy (semaglutide) injection (2.4 mg once weekly) as a medication for chronic weight control in individuals with obesity or those who are overweight with at least one weight-related disease, such as high blood pressure, high cholesterol, or type 2 diabetes, in June 2021. The medication can be taken along with a lower calorie diet and more exercise. Since 2014, this subcutaneous injection is the first medication to be licenced for managing chronic weight in individuals who are obese or overweight. Patients with a body mass index (BMI) of 27 kg/m2 or above who have at least one weight-related condition, as well as those with a BMI of 30 kg/m2 or more, are advised to use it.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Pediatric Obesity Management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug Class, Route of Administration, Distribution Channel & Region.

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16761

Key Segments Profiled in the Pediatric Obesity Management Industry Survey

Drug Class:

• Lorcaserin
• Liraglutide
• Phentermine
• Setmelanotide
• Others

Route of Administration:

• Oral
• Injectable

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com